Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors
by
Ingram, Davis R
, Briaire-de Bruijn, Inge H
, Lev, Dina C
, Somaiah, Neeta
, Bovée, Judith VMG
, Endo, Makoto
, Lim, Simin
, de Graaff, Marieke A
, Lazar, Alexander J
, Nielsen, Torsten O
in
13/51
/ 631/67/1798
/ 692/308/1892
/ 692/699/67/1798
/ Antigens, Neoplasm - metabolism
/ Bone Neoplasms - metabolism
/ Bone Neoplasms - pathology
/ Humans
/ Laboratory Medicine
/ Medicine
/ Medicine & Public Health
/ Membrane Proteins - metabolism
/ original-article
/ Pathology
/ Sarcoma - metabolism
/ Sarcoma - pathology
/ Soft Tissue Neoplasms - metabolism
/ Soft Tissue Neoplasms - pathology
/ Tissue Array Analysis
2015
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors
by
Ingram, Davis R
, Briaire-de Bruijn, Inge H
, Lev, Dina C
, Somaiah, Neeta
, Bovée, Judith VMG
, Endo, Makoto
, Lim, Simin
, de Graaff, Marieke A
, Lazar, Alexander J
, Nielsen, Torsten O
in
13/51
/ 631/67/1798
/ 692/308/1892
/ 692/699/67/1798
/ Antigens, Neoplasm - metabolism
/ Bone Neoplasms - metabolism
/ Bone Neoplasms - pathology
/ Humans
/ Laboratory Medicine
/ Medicine
/ Medicine & Public Health
/ Membrane Proteins - metabolism
/ original-article
/ Pathology
/ Sarcoma - metabolism
/ Sarcoma - pathology
/ Soft Tissue Neoplasms - metabolism
/ Soft Tissue Neoplasms - pathology
/ Tissue Array Analysis
2015
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors
by
Ingram, Davis R
, Briaire-de Bruijn, Inge H
, Lev, Dina C
, Somaiah, Neeta
, Bovée, Judith VMG
, Endo, Makoto
, Lim, Simin
, de Graaff, Marieke A
, Lazar, Alexander J
, Nielsen, Torsten O
in
13/51
/ 631/67/1798
/ 692/308/1892
/ 692/699/67/1798
/ Antigens, Neoplasm - metabolism
/ Bone Neoplasms - metabolism
/ Bone Neoplasms - pathology
/ Humans
/ Laboratory Medicine
/ Medicine
/ Medicine & Public Health
/ Membrane Proteins - metabolism
/ original-article
/ Pathology
/ Sarcoma - metabolism
/ Sarcoma - pathology
/ Soft Tissue Neoplasms - metabolism
/ Soft Tissue Neoplasms - pathology
/ Tissue Array Analysis
2015
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
NY-ESO-1 (CTAG1B) expression in mesenchymal tumors
2015
Request Book From Autostore
and Choose the Collection Method
Overview
New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions. On the basis of these findings, nearly 90% of myxoid liposarcomas, as well as a significant proportion of synovial sarcomas, myxofibrosarcomas, and conventional chondrosarcomas are good candidates for immunotherapy targeting NY-ESO-1.
Publisher
Nature Publishing Group US,Elsevier Limited
This website uses cookies to ensure you get the best experience on our website.